References
- Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245
- Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles F J, Rogers A, Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002; 99: 2265–2267
- Lundberg L G, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. American Journal of Pathology 2000; 157: 15–19
- Molica S, Santoro R, Iuliano F, Di Raimondo F, Fichera E, Giustolisi R. A comparative study with emphasis on myeloproliferative disorders. Haematologica 2001; 86: 771, Serum levels of vascular endothelial growth factor in chronic leukemias
- Ebos J M, Tran J, Master Z, Dumont D, Melo J V, Buchdunger E, Kerbel R S. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Molecular Cancer Research 2002; 1: 89–95
- Legros L, Bourcier C, Jacquel A, Mahon F X, Cassuto J P, Auberger P, Pages G. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 2004; 104: 495–501
- Mangi M H, Newland A C. Angiogenesis and angiogenic mediators in haematological malignancies. British Journal of Haematology 2000; 111: 43–51
- Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim J A, Turner A R, Ratajczak M Z. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 2002; 16: 1160–1166
- Mayerhofer M, Valent P, Sperr W R, Griffin J D, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1 alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767–3775
- Krejci P, Dvorakova D, Krahulcova E, Pachernik J, Mayer J, Hampl A, Dvorak P. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia 2001; 15: 228–237
- Musolino C, Calabro L, Bellomo G, Martello F, Loteta B, Pezzano C, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. American Journal of Hematology 2002; 69: 159–163
- Zhang B, Lewis S M. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. European Journal of Haematology 1989; 43: 63–66
- George T I, Arber D A. Pathology of the myeloproliferative diseases. Hematology & Oncology Clinics of North America 2003; 17: 1101–1127
- Shaked Y, Cervi D, Neuman M, Chen L, Klement G, Michaud C R, et al. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood 2005; 105: 4500–4507
- Mesa R A, Hanson C A, Rajkumar S V, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374–3380
- Murphy P, Ahmed N, Hassan H T. Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera. Leukemia Research 2002; 26: 1007–1010
- Raimondo F D. Angiogenesis in hematology: a field of active research. Leukemia Research 2003; 2: 571–573
- Sillaber C, Mayerhofer M, Aichberger K J, Krauth M T, Valent P. Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. European Journal of Clinical Investigations 2004; 34(Suppl 2)2–11